3.54
-0.15 (-3.94%)
| Previous Close | 3.68 |
| Open | 3.69 |
| Volume | 143,725 |
| Avg. Volume (3M) | 659,714 |
| Market Cap | 468,659,712 |
| Price / Sales | 0.930 |
| Price / Book | 1.52 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -1.62% |
| Operating Margin (TTM) | 5.42% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | 6.10% |
| Quarterly Earnings Growth (YOY) | 289.40% |
| Total Debt/Equity (MRQ) | 38.65% |
| Current Ratio (MRQ) | 3.09 |
| Operating Cash Flow (TTM) | 13.88 M |
| Levered Free Cash Flow (TTM) | 13.47 M |
| Return on Assets (TTM) | 1.64% |
| Return on Equity (TTM) | -2.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Organogenesis Holdings Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -1.38 |
|
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 46.36% |
| % Held by Institutions | 50.88% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Nov 2024 | Announcement | Organogenesis Expands Manufacturing Capacity to Support Future Growth |
| 15 Nov 2024 | Announcement | Organogenesis Commends Final LCDs |
| 12 Nov 2024 | Announcement | Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results |
| 12 Nov 2024 | Announcement | Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock |
| 11 Nov 2024 | Announcement | Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis |
| 16 Oct 2024 | Announcement | Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |